Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma
Krishan R. Jethwa(Mayo Clinic), Suzanne Russo(Case Western Reserve University), William Small(Northwestern University), Jordan Berlin(Dana-Farber Cancer Institute), Timothy J. Kennedy(Memorial Sloan Kettering Cancer Center), Gerard Abood, Christopher L. Hallemeier(Mayo Clinic in Arizona), Navesh Sharma(Penn State Milton S. Hershey Medical Center), Leila T. Tchelebi(Donald & Barbara Zucker School of Medicine at Hofstra/Northwell), Salma K. Jabbour(Rutgers, The State University of New Jersey), Vonetta M. Williams(Memorial Sloan Kettering Cancer Center), Edward Kim(Rutgers, The State University of New Jersey), Percy Lee(University of California, Los Angeles), Rachit Kumar(The University of Texas MD Anderson Cancer Center), Christopher J. Anker(University of Vermont)
Cited by 4
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy for the Definitive Treatment of Cervix Cancer
|International Journal of Radiation Oncology*Biology*Physics|2010|458
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer
|International Journal of Radiation Oncology*Biology*Physics|2007|415